zotarolimus has been researched along with Drug-Hypersensitivity* in 3 studies
3 other study(ies) available for zotarolimus and Drug-Hypersensitivity
| Article | Year |
|---|---|
Hypersensitivity reaction in the US Food and Drug Administration-approved second-generation drug-eluting stents: histopathological assessment with ex vivo optical coherence tomography.
Topics: Drug Hypersensitivity; Drug-Eluting Stents; Humans; Male; Middle Aged; Sirolimus; Tomography, Optical Coherence; United States; United States Food and Drug Administration | 2015 |
Zotarolimus-eluting stent-induced hypersensitivity pneumonitis.
Topics: Alveolitis, Extrinsic Allergic; Biopsy; Drug Hypersensitivity; Drug-Eluting Stents; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Sirolimus; Steroids; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression.
Sirolimus (rapamycin) is an immunosuppressant used in preventing allograft rejection and in drug-eluting stents to prevent restenosis after angioplasty. Zotarolimus, an analogue of sirolimus, was designed to have a shorter in vivo half-life. Zotarolimus was found to be mechanistically similar to sirolimus in having high-affinity binding to the immunophilin FKBP12 and comparable potency for inhibiting in vitro proliferation of both human and rat T cells. Rat pharmacokinetic studies with intravenous dosing demonstrated terminal elimination half-lives of 9.4 hours and 14.0 hours for zotarolimus and sirolimus, respectively. Given orally, T1/2 values were 7.9 hours and 33.4 hours, respectively. Consistent with its shorter duration, zotarolimus showed a corresponding and statistically significant 4-fold reduction in potency for systemic immunosuppression in 3 rat disease models. Pharmacokinetic studies in cynomolgus monkey underpredicted the half-life difference between zotarolimus and sirolimus apparent from recent clinical data. In vitro inhibition of human coronary artery smooth muscle cell proliferation by zotarolimus was comparable to sirolimus. Drug-eluting stents for local delivery of zotarolimus to the vessel wall of coronary arteries are in clinical development. The pharmacological profile of zotarolimus suggests it may be advantageous for preventing restenosis with a reduced potential for causing systemic immunosuppression or other side effects. Topics: Animals; Animals, Newborn; Binding, Competitive; Cell Proliferation; Coronary Vessels; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Hypersensitivity; Encephalomyelitis, Autoimmune, Experimental; Graft Rejection; Half-Life; Heart Transplantation; Humans; Hypersensitivity, Delayed; Immunosuppressive Agents; Inhibitory Concentration 50; Lymphocyte Culture Test, Mixed; Male; Myocytes, Smooth Muscle; Rats; Rats, Inbred BN; Rats, Inbred Lew; Rats, Sprague-Dawley; Sirolimus; T-Lymphocytes; Tacrolimus Binding Protein 1A | 2007 |